Figure 1.
Identification of key circulating miRNAs by microarray probes. A. MiRNAs expression between bladder cancer and normal samples. B. Circulating miRNAs in high stage compared to low stage bladder cancer samples.
Citation: Guobing Lin, Cunming Zhang, Xuanyu Chen, Junwei Wang, Song Chen, Siyuan Tang, Tianqiang Yu. Identification of circulating miRNAs as novel prognostic biomarkers for bladder cancer[J]. Mathematical Biosciences and Engineering, 2020, 17(1): 834-844. doi: 10.3934/mbe.2020044
| [1] | Guohong Xin, Xiaoci Cao, Wujie Zhao, Pintian Lv, Gang Qiu, Yaxing Li, Bin Wang, Baoshuan Fang, Yitao Jia . MicroRNA expression profile and TNM staging system predict survival in patients with lung adenocarcinoma. Mathematical Biosciences and Engineering, 2020, 17(6): 8074-8083. doi: 10.3934/mbe.2020409 |
| [2] | Zekun Xin, Yang Li, Lingyin Meng, Lijun Dong, Jing Ren, Jianlong Men . Elevated expression of the MYB proto-oncogene like 2 (MYBL2)-encoding gene as a prognostic and predictive biomarker in human cancers. Mathematical Biosciences and Engineering, 2022, 19(2): 1825-1842. doi: 10.3934/mbe.2022085 |
| [3] | Ahmed Hammad, Mohamed Elshaer, Xiuwen Tang . Identification of potential biomarkers with colorectal cancer based on bioinformatics analysis and machine learning. Mathematical Biosciences and Engineering, 2021, 18(6): 8997-9015. doi: 10.3934/mbe.2021443 |
| [4] | Meng Chen, Dacheng Jin, Bing Wang, Yunjiu Gou, Xinchun Dong . Identification of miRNAs as prognostic factors for esophageal squamous cell carcinoma. Mathematical Biosciences and Engineering, 2020, 17(3): 2302-2309. doi: 10.3934/mbe.2020122 |
| [5] | Linbo Zhang, Mei Xin, Peng Wang . Identification of a novel snoRNA expression signature associated with overall survival in patients with lung adenocarcinoma: A comprehensive analysis based on RNA sequencing dataset. Mathematical Biosciences and Engineering, 2021, 18(6): 7837-7860. doi: 10.3934/mbe.2021389 |
| [6] | Peiyuan Li, Gangjie Qiao, Jian Lu, Wenbin Ji, Chao Gao, Feng Qi . PVT1 is a prognostic marker associated with immune invasion of bladder urothelial carcinoma. Mathematical Biosciences and Engineering, 2022, 19(1): 169-190. doi: 10.3934/mbe.2022009 |
| [7] | Ming-Xi Zhu, Tian-Yang Zhao, Yan Li . Insight into the mechanism of DNA methylation and miRNA-mRNA regulatory network in ischemic stroke. Mathematical Biosciences and Engineering, 2023, 20(6): 10264-10283. doi: 10.3934/mbe.2023450 |
| [8] | Hao Shen, Xiao-Dong Weng, Du Yang, Lei Wang, Xiu-Heng Liu . Long noncoding RNA MIR22HG is down-regulated in prostate cancer. Mathematical Biosciences and Engineering, 2020, 17(2): 1776-1786. doi: 10.3934/mbe.2020093 |
| [9] | Jie Qiu, Maolin Sun, Chuanshan Zang, Liwei Jiang, Zuorong Qin, Yan Sun, Mingbo Liu, Wenwei Zhang . Five genes involved in circular RNA-associated competitive endogenous RNA network correlates with metastasis in papillary thyroid carcinoma. Mathematical Biosciences and Engineering, 2021, 18(6): 9016-9032. doi: 10.3934/mbe.2021444 |
| [10] | Eugene Kashdan, Svetlana Bunimovich-Mendrazitsky . Hybrid discrete-continuous model of invasive bladder cancer. Mathematical Biosciences and Engineering, 2013, 10(3): 729-742. doi: 10.3934/mbe.2013.10.729 |
Abbreviations: miRNA: MicroRNA; FC: Fold change; FDR: False discovery rate; SD: Standard deviation.
MicroRNA (miRNA) is a type of ncRNAs with 18–25 nucleotides in length and reported to play crucial roles in human cancers [1]. MiRNAs regulated multiple cancers related biological processes, including cell proliferation, cell migration, cell apoptosis and cancer autophagy. Of note, the dysregulation of miRNAs were found to be associated with the progression and the prognosis of cancers. For example, Asano et al. reported a serum microRNA classifier for the diagnosis of sarcomas of various histological subtypes [2]. Of note, previous studies had showed that the computational analysis of microarray datasets is a powerful tool to identify bladder cancer related miRNAs. For example, Falzone et al. identified epithelial to mesenchymal transition and NGAL/MMP-9 pathways related microRNAs in bladder cancer using bioinformatics analysis [3]. And Falzone et al. identified a series of novel microRNAs and their diagnostic and prognostic Significance in Oral Cancer [4]. Therefore, exploring the functions and expression levels of miRNAs could provide novel biomarkers for human cancers.
Bladder cancer is one of the most common causes of cancer-related death. The 5-year survival rate of distant metastatic bladder cancer is about 10–35% [5]. The discovery of new early biomarkers for BC may improve the patients' response to the treatment thus obtaining higher outcomes. The most widely used diagnostic methods, including urinary cytology, ultrasound and cystoscopy, remain unsatisfactory due to low accuracy. Of note, emerging studies demonstrated the important roles of miRNAs in bladder cancer. For example, miR-4324 inhibits bladder cancer proliferation and metastasis though RACGAP1-STAT3-ESR1 feedback loop [6]. Moreover, recent studies showed circulating miRNA by liquid biopsy could be the potential biomarker for bladder cancer. Du et al. found miR-7-5p, miR-22-3p, miR-29a-3p, miR-126-5p, miR-200a-3p, miR-375, and miR-423-5p in urine could serve as noninvasive biomarkers for bladder cancer [7]. Jiang et al. found, miR-148b-3p, miR-3187-3p, miR-15b-5p, miR-27a-3p and miR-30a-5p in serum samples could be the potential biomarkers for the prognosis of bladder cancer [8].
In this study, to identify differentially expressed miRNAs in bladder cancer serum samples by analyzing GSE113486 [9]. We identified 7 miRNAs signature involved in the prognosis of bladder cancer. Moreover, we conducted GO and KEGG analysis to explore molecular mechanisms of aberrantly expressed miRNAs.
The main aim of this study is to identify potential biomarker for the prognosis of bladder cancer. Previous studies demonstrated that circulating miRNA by liquid biopsy could be the potential noninvasive diagnostic target for bladder cancer. Thus, we analyzed a serum dataset, GSE113486, instead of analyzing tumor tissues and normal counterpart datasets. In our study, we screened differently expressed miRNAs in bladder cancer samples using the public dataset, GSE113486. Totally, 392 bladder cancer samples 100 non-cancer control samples were included in this dataset. The raw datasets of from GSE113486 were downloaded and preprocessed by log2 transformation and Z-score normalisation. The miRNA, which were differentially expressed between bladder cancer and normal blood samples, were identified by the linear models for microarray analysis (Limma) method. The P-value, false discovery rate and fold change were calculated for each miRNA. Only miRNAs with | log2 fold change (FC)| ≥ 1.0 and false discovery rate (FDR) ≤ 0.01 were regarded as differently expressed miRNAs.
The DAVID system (http://david.ncifcrf.gov/) was used to perform to determine the biological roles of differentially expressed mRNAs [10]. Gene functions were classified into three subetaoups namely BP, CC and MF. The enriched GO terms were presented by enrichment scores. KEGG pathway analysis was carried out to determine the involvement of differentially expressed mRNAs in different biological pathways. The recommend p value (Hypergeometric-P value) cut-off is 0.05.
The numerical data were presented as mean ± standard deviation (SD) of at least three determinations. Statistical comparisons between groups of normalized data were performed using T-test or Mann–Whitney U-test according to the test condition. A p < 0.05 was considered statistical significance with a 95% confidence level.
The public dataset, GSE113486, was analyzed to identify differentially expressed circulating miRNAs in bladder cancer. Totally, there are 392 bladder cancer samples and 100 non-cancer control samples were included in this dataset. By comparing the miRNAs expression between bladder cancer and normal samples, we identified 2218 differentially expressed circulating miRNAs (Figure 1A).
Furthermore, we screened differentially expressed circulating miRNAs in high stage compared to low stage bladder cancer samples. As present in Figure 1B, there are 158 miRNAs that were identified to be dysregulated.
Of note, we analyzed ONCOMIR dataset to identify prognosis related miRNAs in bladder cancer. A total of 144 miRNAs were found to be associated with the overall time in patients with bladder cancer samples (Supplementary Table 1).
Finally, seven miRNAs were identified to be dysregulated in bladder cancer serum samples and correlated to the advanced stage and overall survival time in patients with bladder cancer, including hsa-miR-185-5p, hsa-miR-663a, hsa-miR-30c-5p, hsa-miR-3648, hsa-miR-1270, hsa-miR-200c-3p, and hsa-miR-29c-5p.
As present in Figure 2, the present study showed hsa-miR-185-5p, hsa-miR-663a, hsa-miR-30c-5p, hsa-miR-3648, hsa-miR-1270, hsa-miR-200c-3p, and hsa-miR-29c-5p were significantly overexpressed in bladder cancer serum samples. Among them, hsa-miR-663a showed the most significantly up-regulation in bladder cancer samples compared to normal samples.
As present in Figure 3, the present study also showed hsa-miR-663a and hsa-miR-3648 was significantly up-regulated in pathological t stage ≥ pT2 compared to pathological t stage < pT2 bladder cancer samples. Interestingly, we found hsa-miR-185-5p, hsa-miR-30c-5p, hsa-miR-1270, hsa-miR-200c-3p, and hsa-miR-29c-5p were down-regulated in pathological t stage ≥ pT2 compared to pathological t stage < pT2 bladder cancer samples.
In order to determine the prognostic value of seven differentially expressed miRNAs in bladder cancer, Kaplan-Meier survival curve analyses were conducted by using TCGA database [11]. As present in Figure 4, the present study also showed higher expression of hsa-miR-663a and hsa-miR-3648, and lower expression of hsa-miR-185-5p, hsa-miR-30c-5p, hsa-miR-1270, hsa-miR-200c-3p, and hsa-miR-29c-5p were significantly correlated to shorter overall survival time in patients with bladder cancer. There results suggested showed these abnormally expressed miRNAs were associated with cancer progression and could acted as diagnostic biomarkers in bladder cancer.
Then, the ONCOMIR dataset [12] was used to identify a predictive model to predict the prognosis of bladder cancer, as follows: Risk score = (2.254 × expression value of miR-185-5p) + (2.439 × expression value of miR-663a) + (2.429 × expression value of miR-30c-5p) + (2.617 × expression value of miR-3648) + (2.720 × expression value of miR-1270) + (2.298 × expression value of miR-200c-3p) + (3.089 × expression value of miR-29c-5p). As shown in Figure 4H, Kaplan-Meier survival curve analyses showed that bladder cancer patients with high-risk scores had significantly worse OS than bladder patients with lower risk scores.
To predict the targets of differentially expressed miRNAs, we used four different databases including TargetScan, miRWALK [13], miRDB [14], and starbase [15] (Figure 3A). A total of 605 targets were obtained. The present study selected the down-regulated genes as potential targets of up-regulated miRNAs and the up-regulated genes as potential targets of down-regulated miRNAs. Accordingly, the network between differentially expressed targets and miRNAs was constructed using Cytoscape v3.2.1 software [16] (Figure 5A). A total of 48 key genes were found to be regualted by more than 2 differently expressed miRNAs, including ALS2CR11, KIAA1244, TULP4, KIAA1522, MNT, PRR14L, FADD, SNX30, VAT1, PCDHA10, GNPDA1, C6orf120, CRABP2, N4BP1, GPR107, SAMD5, ZNF562, DGKQ, TBX15, EXOC4, TK2, FRK, L3MBTL3, GTF3C3, ELMOD2, ZNF585A, PHACTR2, PHF6, PVRL4, NAALADL2, RTCB, TMEM33, TMEM121, SPAG9, RABGAP1L, MEX3D, GAN, ARHGAP29, C6orf141, DNAJC5, RNF40, PDP2, CTNND1, PIK3C2G, ACADSB, CCDC173, TET2 and B3GAT1.
We performed GO analysis for differentially expressed miRNAs by using the target mRNAs (Figure 5B). According to the GO analysis, differentially expressed miRNAs were enriched in Bioinformatics analysis revealed these miRNAs were involved in regulating sarcomere organization, positive regulation of multicellular organism growth, spleen development, phosphorylation, phosphatidylinositol-mediated signaling, and peroxisome proliferator activated receptor signaling pathway.
One of the biggest challenge for bladder cancer treatment was the absence of early diagnostic biomarkers. In the past decade, emerging studies showed circulating miRNA by liquid biopsy could be the potential biomarker for human diseases, including cancers. In bladder cancer, Du et al. found miR-7-5p, miR-22-3p, miR-29a-3p, miR-126-5p, miR-200a-3p, miR-375 and miR-423-5p in urine could serve as noninvasive biomarkers for bladder cancer. Jiang et al. found miR-152, miR-148b-3p, miR-3187-3p, miR-15b-5p, miR-27a-3p and miR-30a-5p in serum samples could be the potential biomarkers for the prognosis of bladder cancer. However, these reports identified their targets using a small size samples lacked systems-level identification of differentially expressed miRNAs in a large sample size. The present study identified 7 miRNAs panel (hsa-miR-185-5p, hsa-miR-663a, hsa-miR-30c-5p, hsa-miR-3648, hsa-miR-1270, hsa-miR-200c-3p and hsa-miR-29c-5p) for the diagnosis of bladder cancer. Our results showed these miRNAs were significantly overexpressed in bladder cancer serum samples, and correlated to advanced stage and overall survival time in patients with bladder cancer. We thought this study could provide novel noninvasive early biomarkers for bladder cancer.
MiRNAs were a type of ncRNAs with 19–25 nt length. Emerging studies demonstrated that MiRNAs played crucial roles in the tumorigenesis and progression of human cancers. The present study showed hsa-miR-185-5p, hsa-miR-663a, hsa-miR-30c-5p, hsa-miR-3648, hsa-miR-1270, hsa-miR-200c-3p, and hsa-miR-29c-5p were overexpressed in bladder cancer. Interestingly, we found hsa-miR-663a and hsa-miR-3648 were significantly up-regulated, however, hsa-miR-185-5p, hsa-miR-30c-5p, hsa-miR-1270, hsa-miR-200c-3p, and hsa-miR-29c-5p were down-regulated in advanced stage bladder cancer compared to low stage cancer samples. These results suggest hsa-miR-185-5p, hsa-miR-30c-5p, hsa-miR-1270, hsa-miR-200c-3p, and hsa-miR-29c-5p may play promoting roles in tumorigeneses and play tumor suppressive roles in cancer development. Of note, several miRNAs had been report to play important roles in multiple human cancers, including bladder cancer. For example, miR-185-5p promotes prostate cancer apoptosis and inhibits osteosarcoma cell proliferation and metastasis by targeting VAMP2 [17]. Two recent studies also showed miR-185 was up-regulated in bladder cancer samples [18]. miR-663a functioned as either an oncogene or a tumor suppressor. miR-663a suppressed hepatocellular carcinoma growth and invasion by regulating TGF-β1 [19]. However, in renal cell carcinoma, miR-663a served as an oncogene [20]. miR-200c was a well-known miRNA involved in regulating cancer progression, EMT, and drug resistance. In bladder cancer, miR-200c inhibits cancer progression by targeting LDHA [21].
In present study, we constructed differently expressed miRNAs-mRNAs networks and performed GO and KEGG analysis by using the target mRNAs. A total of 11 miRNAs and 267 mRNAs were included in this network. Four miRNAs, including hsa-miR-93-5p, hsa-miR-15b-5p, hsa-let-7i-5p, and hsa-miR-204-5p were identified as key regulators in this network by regulating more than 40 mRNAs in GC. Bioinformatics analysis revealed these miRNAs were involved in regulating sarcomere organization, positive regulation of multicellular organism growth, spleen development, phosphorylation, phosphatidylinositol-mediated signaling, and peroxisome proliferator activated receptor signaling pathway.
In conclusion, the present study identified 7 miRNAs were up-regulated in bladder serum cancer samples compared to normal samples, including hsa-miR-185-5p, hsa-miR-663a, hsa-miR-30c-5p, hsa-miR-3648, hsa-miR-1270, hsa-miR-200c-3p and hsa-miR-29c-5p. The dysregulation of these miRNAs were correlated to advanced stage and overall survival time in bladder cancer patients. Moreover, we identified a predictive model to predict the prognosis of bladder cancer. Kaplan-Meier survival curve analyses showed that bladder cancer patients with high-risk scores had significantly worse overall survival time than bladder patients with lower risk scores. Furthermore, we constructed a miRNA-mRNA regulating network. Bioinformatics analysis showed these miRNAs were involved in regulating sarcomere organization, positive regulation of multicellular organism growth, phosphorylation, phosphatidylinositol-mediated signaling, and peroxisome proliferator activated receptor signaling pathway. We thought this study could provide novel noninvasive early biomarkers for bladder cancer.
The authors declared no conflict of interest.
| [1] | A. Q. Gomes, S. Nolasco and H. Soares, Non-coding RNAs: Multi-tasking molecules in the cell, Int. J. Mol. Sci., 14 (2013), 16010-16039. |
| [2] | N. Asano, J. Matsuzaki, M. Ichikawa, et al., A serum microRNA classifier for the diagnosis of sarcomas of various histological subtypes, Nat. Commun., 10 (2019), 1299. |
| [3] | L. Falzone, S. Candido, R. Salemi, et al., Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer, Oncotarget, 7 (2016), 72758-72766. |
| [4] | L. Falzone, G. Lupo, G. R. M. L. Rosa, et al., Identification of Novel MicroRNAs and Their Diagnostic and Prognostic Significance in Oral Cancer, Cancers, 11 (2019), 610. |
| [5] | P. Anand, A. B. Kunnumakara, C. Sundaram, et al., Cancer is a Preventable Disease that Requires Major Lifestyle Changes, Pharm. Res., 25 (2008), 2097-2116. |
| [6] | T. Inamoto, H. Uehara, Y. Akao, et al., A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder, Dis. Markers, 2018 (2018), 5468672. |
| [7] | Y. He, J. Lin, D. Kong, et al., Current State of Circulating MicroRNAs as Cancer Biomarkers, Clin. Chem., 61 (2015), 1138-1155. |
| [8] | X. Jiang, L. Du, W. Duan, et al., Serum microRNA expression signatures as novel noninvasive biomarkers for prediction and prognosis of muscle-invasive bladder cancer, Oncotarget, 7 (2016), 36733-36742. |
| [9] | W. Usuba, F. Urabe, Y. Yamamoto, et al., Circulating miRNA panels for specific and early detection in bladder cancer, Cancer Sci., 110 (2019), 408-419. |
| [10] | D. W. Huang, B. T. Sherman and R. A. Lempicki, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources, Nat. Protoc., 4 (2009), 44-57. |
| [11] | Z. Wang, M. A. Jensen and J. C. Zenklusen, A Practical Guide to The Cancer Genome Atlas (TCGA), in Statistical Genomics, Humana Press, New York, (2016), 111-141. |
| [12] | N. Wong, Y. Chen, S. Chen, et al., OncomiR: An online resource for exploring pan-cancer microRNA dysregulation, Bioinformatics, 34 (2018), 713-715. |
| [13] | C. Sticht, C. D. La Torre, A. Parveen, et al., miRWalk: An online resource for prediction of microRNA binding sites, Plos One, 13 (2018), e0206239. |
| [14] | N. Wong and X. Wang, miRDB: An online resource for microRNA target prediction and functional annotations, Nucleic Acids Res., 43 (2015), D146-D152. |
| [15] | J. Yang, J. Li, P. Shao, et al., starBase: A database for exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data, Nucleic Acids Res., 39 (2011), D202-D209. |
| [16] | P. Shannon, A. Markiel, O. Ozier, et al., Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks, Genome Res., 13 (2003), 2498-2504. |
| [17] | S. Ostadrahimi, S. Fayaz, M. Parvizhamidi, et al., Downregulation of miR-1266-5P, miR-185-5P and miR-30c-2 in prostatic cancer tissue and cell lines, Oncol. Lett., 15 (2018), 8157-8164. |
| [18] | F. Qu, X. Cui, Y. Hong, et al., MicroRNA-185 suppresses proliferation, invasion, migration, and tumorigenicity of human prostate cancer cells through targeting androgen receptor, Mol. Cell. Biochem., 377 (2013), 121-130. |
| [19] | C. Zhang, B. Chen, A. Jiao, et al., miR-663a inhibits tumor growth and invasion by regulating TGF-beta1 in hepatocellular carcinoma, BMC Cancer, 18 (2018), 1179. |
| [20] | Y. Zhang, X. Xu, M. Zhang, et al., MicroRNA-663a is downregulated in non-small cell lung cancer and inhibits proliferation and invasion by targeting JunD, BMC Cancer, 16 (2016), 315. |
| [21] | H. Tang, M. Deng, Y. Tang, et al., miR-200b and miR-200c as Prognostic Factors and Mediators of Gastric Cancer Cell Progression, Clin. Cancer Res., 19 (2013), 5602-5612. |
| 1. | Meng Wu, Qingdai Li, Hongbing Wang, Identification of Novel Biomarkers Associated With the Prognosis and Potential Pathogenesis of Breast Cancer via Integrated Bioinformatics Analysis, 2021, 20, 1533-0346, 153303382199208, 10.1177/1533033821992081 | |
| 2. | Wei Wang, Pengfei Wang, Kaihui Xie, Ruirui Luo, Xiaoli Gao, Zunqiang Yan, Xiaoyu Huang, Qiaoli Yang, Shuangbao Gun, ssc-miR-185 targets cell division cycle 42 and promotes the proliferation of intestinal porcine epithelial cell, 2021, 34, 2765-0189, 801, 10.5713/ajas.20.0325 | |
| 3. | Ishaq Tantray, Rani Ojha, Aditya P. Sharma, Non-coding RNA and autophagy: Finding novel ways to improve the diagnostic management of bladder cancer, 2023, 13, 1664-8021, 10.3389/fgene.2022.1051762 | |
| 4. | An-Lun Li, Che-Yi Chou, Chien-Lung Chen, Kun-Lin Wu, Shih-Chieh Lin, Hung-Chun Chen, Ming-Cheng Wang, Chia-Chu Chang, Bang-Gee Hsu, Mai-Szu Wu, Nianhan Ma, Chiu-Ching Huang, The MicroRNA Prediction Models as Ancillary Diagnosis Biomarkers for Urothelial Carcinoma in Patients With Chronic Kidney Disease, 2021, 8, 2296-858X, 10.3389/fmed.2021.726214 | |
| 5. | Lei Yang, Hong-Fang Sun, Lin-Qing Guo, Hai-Bing Cao, MiR-10a-5p: A Promising Biomarker for Early Diagnosis and Prognosis Evaluation of Bladder Cancer, 2021, Volume 13, 1179-1322, 7841, 10.2147/CMAR.S326732 | |
| 6. | Tessa A. C. M. Vissers, Leonie Piek, Susana I. S. Patuleia, Aafke J. Duinmeijer, Marije F. Bakker, Elsken van der Wall, Paul J. van Diest, Carla H. van Gils, Cathy B. Moelans, Elevated miR-29c-5p Expression in Nipple Aspirate Fluid Is Associated with Extremely High Mammographic Breast Density, 2022, 14, 2072-6694, 3805, 10.3390/cancers14153805 | |
| 7. | Wei Wang, Jun Zhang, YunXiu Fan, Li Zhang, MiR-1306-5p predicts favorable prognosis and inhibits proliferation, migration, and invasion of colorectal cancer cells via PI3K/AKT/mTOR pathway, 2022, 21, 1538-4101, 1491, 10.1080/15384101.2022.2054245 | |
| 8. | Chao Wang, Huamao Jiang, Long Non-Coding RNA PCAT19 Regulates the Malignant Progression of Bladder Cancer through the miR-335-5p/IER2 Axis , 2022, 32, 1045-4403, 81, 10.1615/CritRevEukaryotGeneExpr.2022043175 | |
| 9. | Zhenhe Song, Jian Wang, LncRNA ASMTL-AS1/microRNA-1270 differentiate prognostic groups in gastric cancer and influence cell proliferation, migration and invasion, 2022, 13, 2165-5979, 1507, 10.1080/21655979.2021.2021063 | |
| 10. | Dominic Robles, De-Huang Guo, Noah Watson, Diana Asante, Sangeetha Sukumari-Ramesh, Dysregulation of Serum MicroRNA after Intracerebral Hemorrhage in Aged Mice, 2023, 11, 2227-9059, 822, 10.3390/biomedicines11030822 | |
| 11. | Z. Wen, G. Huang, Y. Lai, L. Xiao, X. Peng, K. Liu, C. Zhang, X. Chen, R. Li, X. Li, Y. Lai, L. Ni, Diagnostic panel of serum miR-125b-5p, miR-182-5p, and miR-200c-3p as non-invasive biomarkers for urothelial bladder cancer, 2022, 24, 1699-3055, 909, 10.1007/s12094-021-02741-3 | |
| 12. | Thuy T. P. Nguyen, Kamrul Hassan Suman, Thong Ba Nguyen, Ha Thi Nguyen, Duy Ngoc Do, The Role of miR-29s in Human Cancers—An Update, 2022, 10, 2227-9059, 2121, 10.3390/biomedicines10092121 | |
| 13. | Yanhong Tu, Fan Mei, miR-3648 promotes lung adenocarcinoma-genesis by inhibiting SOCS2 (suppressor of cytokine signaling 2), 2022, 13, 2165-5979, 3044, 10.1080/21655979.2021.2017577 | |
| 14. | Lu Qi, Lu Wang, Fuyao Song, Zhenhua Ding, Ying Zhang, The role of miR-4469 as a tumor suppressor regulating inflammatory cell infiltration in colorectal cancer, 2022, 20, 20010370, 3755, 10.1016/j.csbj.2022.07.021 | |
| 15. | ChauMyThanh Tran, PhongSon Dinh, Potential diagnostic value of serum microRNAs for 19 cancer types: a meta-analysis of bioinformatics data, 2024, 0739-1102, 1, 10.1080/07391102.2024.2328744 | |
| 16. | Safoora Pordel, Motahare Khorrami, Fatemeh Saadatpour, Delsuz Rezaee, William C. Cho, Saleheh Jahani, Seyed Mohsen Aghaei-Zarch, Elham Hashemi, Sajad Najafi, The role of microRNA-185 in the pathogenesis of human diseases: A focus on cancer, 2023, 249, 03440338, 154729, 10.1016/j.prp.2023.154729 | |
| 17. | Sihai Lu, Xiaobin Zhang, Zhiye Cai, Ziyi Xi, Fei Wang, Xuan Wang, Wenqi Li, Penggao Dai, Identification of novel lncRNA prognostic biomarkers and their associated ceRNAs in bladder urothelial carcinoma, 2023, 37, 1095-6670, 10.1002/jbt.23441 | |
| 18. | Maria Iyali Torres-Bustamante, Jorge Raul Vazquez-Urrutia, Fabiola Solorzano-Ibarra, Pablo Cesar Ortiz-Lazareno, The Role of miRNAs to Detect Progression, Stratify, and Predict Relevant Clinical Outcomes in Bladder Cancer, 2024, 25, 1422-0067, 2178, 10.3390/ijms25042178 | |
| 19. | Mehrdad Hashem, Elaheh Mohandesi Khosroshahi, Melika Aliahmady, Morvarid Ghanei, Yasamin Soofi Rezaie, Yasamin alsadat Jafari, Fatemeh rezaei, Ramtin Khodaparast eskadehi, Kimia Kia Kojoori, faranak jamshidian, Noushin Nabavi, Mohsen Rashidi, Farzaneh Hasani Sadi, Afshin Taheriazam, Maliheh Entezari, Non-coding RNA transcripts, incredible modulators of cisplatin chemo-resistance in bladder cancer through operating a broad spectrum of cellular processes and signaling mechanism, 2024, 9, 24680540, 560, 10.1016/j.ncrna.2024.01.009 | |
| 20. | Dimitra P. Vageli, Panagiotis G. Doukas, Jeffrey P. Townsend, Curtis Pickering, Benjamin L. Judson, Novel non‐invasive molecular signatures for oral cavity cancer, by whole transcriptome and small non‐coding RNA sequencing analyses: Predicted association with PI3K/AKT/mTOR pathway, 2024, 13, 2045-7634, 10.1002/cam4.7309 | |
| 21. | Xia Ding, Mingjiao Chen, Yan Liu, Tianyi Zhou, Yue Xing, Ming Lin, Jin Li, Non-invasive miRNAs for early detection and diagnosis of lacrimal adenoid cystic carcinoma, 2024, 15, 2730-6011, 10.1007/s12672-024-01436-9 | |
| 22. | Zhenjian Ge, Shengjie Lin, Chong Lu, Yong Xia, Rongkang Li, Xinji Li, Chen Sun, Zhenyu Wen, Wenkang Chen, Yingqi Li, Mingyang Li, Yu Lin, Jing Dong, Lingzhi Tao, Ling Ji, Yongqing Lai, Panel containing three serum microRNAs: a promising biomarker for early detection of bladder cancer, 2024, 14, 2234-943X, 10.3389/fonc.2024.1470457 |
Figures(5)
Guobing Lin, Cunming Zhang, Xuanyu Chen, Junwei Wang, Song Chen, Siyuan Tang, Tianqiang Yu. Identification of circulating miRNAs as novel prognostic biomarkers for bladder cancer[J]. Mathematical Biosciences and Engineering, 2020, 17(1): 834-844. doi: 10.3934/mbe.2020044
DownLoad:
